ResMed Inc. (RMD): analysis and signal as of September 2, 2026
In short
The signal detected on ResMed Inc. (RMD) as of 2 September 2026 is weak, with a 3/3 vote and a deterministic score of -1,00. Fundamental quality is neutralised by a risk layer lacking verified data and by the tax penalty linked to the US-domiciled share.
- Current signal
- weak (vote 3/3)
- Deterministic score
- +2.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower) | -1.5 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
Thesis
ResMed shows measurable fundamental quality, with growth of about 10 %, an operating margin of about 34 %, positive net cash and a share repurchase programme of about 2 Md USD. Healthy flows, driven by intraday institutional movements, support a defensive healthcare model favoured by the macro regime. By contrast, the risk layer remains silent in verified data on the impact of GLP-1, Medicare pricing and the return of Philips, while the deterministic signal stands at -1,00 because of the US tax treatment of the share. No new dated fact has occurred since the verdict of 31/08, hence a carry-over with degraded confidence, one layer out of three delivering no verified data.
Bull case
The fundamentals of fiscal year 2026 support the thesis, with revenue of 5 653 M USD up +9,85 %, earnings per share of 10,34 USD, free cash flow of 1 343 M USD and positive net cash. The institutional flow profile reinforces this reading, with intraday movements at +21,6 % over two years against -20,8 % out of session. The diversifying contribution is real, with an average correlation of 0,10 and volatility of a diversified set reduced by 9,3 % according to the calculations of the analysis.
Bear case
The risk layer documents nothing live, neither the effect of GLP-1 on the prevalence of sleep apnoea, nor Medicare/DMEPOS reimbursement, nor the competition from Philips revived since the 2021 recall, although these themes are precisely the expected catalysts. The deterministic guardrail score remains at -1,00, penalised by the US tax treatment of the share, and the modest dividend does not cushion the valuation premium at a PER of about 24-25.
Scenarios
Three 12-month trajectories are considered. The bullish scenario (~30 %) relies on a PER of about 24 applied to an anticipated earnings per share close to 11,3 USD. The central scenario (~40 %) describes a stabilisation of the price with a performance close to zero. The bearish scenario (~30 %) puts a maximum estimated decline at -25 %, the first threshold being crossed during the technical invalidation.
Risks
The points of vigilance remain the effect of GLP-1 on the prevalence of sleep apnoea, the evolution of Medicare/DMEPOS reimbursement and the competition from Philips revived since the 2021 recall, three topics not documented with verified data. These are compounded by a modest dividend against a PER of about 24-25 and a penalty linked to the US tax treatment. On the technical side, a weekly close below the invalidation threshold defined by the analysis would call the thesis into question.
Market positioning (short sellers)
- Short interest / shares outstanding
- 8.93 %
- Days to cover
- 7.41
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| Q1 FY2027 report, market share gains on Philips recall | |
| Medica conference, new bilevel ventilators |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | No new dated fact between 31/08 and 02/09. The layers provided come from internal analysis, with no external verified data live, and the figures flagged as possibly outdated do not constitute a new fact. The verdict of 31/08 is therefore carried over, and this content is analysis without constituting advice. | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What results were published for fiscal year 2026?
ResMed reports revenue of 5 653 M USD, up +9,85 %. Earnings per share reach 10,34 USD and free cash flow 1 343 M USD. The operating margin stands around 34 %, net cash is positive and the company devotes about 2 Md USD to repurchasing its shares.
Why is the signal described as weak?
Three elements explain this finding. The deterministic guardrail score stands at -1,00, penalised by the US tax treatment of the share. The risk layer delivers no verified data on GLP-1, Medicare reimbursement or competition from Philips. Finally, no new dated fact has occurred since the verdict of 31/08, which leads to carrying over the analysis with degraded confidence.
What do the institutional flows reveal?
The analysis distinguishes intraday flows from out-of-session flows. Over two years, intraday movements rise by +21,6 % while out-of-session flows fall by -20,8 %. This gap suggests an accumulation driven by institutional players during trading hours, which supports the fundamental reading despite a weak overall signal.
What are the main risks identified?
Three expected catalysts still lack verified data: the impact of GLP-1 on the prevalence of sleep apnoea, the evolution of Medicare/DMEPOS pricing and the return of Philips since its 2021 recall. These uncertainties are compounded by a modest dividend, a valuation premium at a PER of about 24-25 and a tax penalty linked to the United States.
How are the 12-month scenarios distributed?
The bullish scenario is estimated at about 30 % probability, the central scenario at about 40 % and the bearish scenario at about 30 %. The central case describes a stabilisation with a performance close to zero. The bearish case puts a maximum estimated decline at -25 %. The bullish case relies on a PER of about 24 applied to an anticipated earnings per share close to 11,3 USD.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 8.01 Other Events (SEC · 8-K)
- — 4.01 Changes in Registrant's Certifying Accountant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Com… (SEC · 8-K)
- — 10-K (SEC · 10-K)
- — 2.02 Results of Operations and Financial Condition; 8.01 Other Events; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits (SEC · 8-K)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 2, 2026; this page was completed on September 3, 2026 at 23:14 (UTC).
- Interests: no position in the stock analysed (RMD) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology